Key facts
- This page summarizes Craig A. Tooman's Form 4 filing for Silence Therapeutics plc (SLN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 06 Jan 2025, 16:15.
Craig A. Tooman - 02 Jan 2025 Form 4 Insider Report for Silence Therapeutics plc (SLN)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- SLN
- Reported as of
- 02 Jan 2025
- Net transaction value
- $0
- Reporting owner signature
- /s/ Rhonda Hellums, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Craig A. Tooman filed Form 4 for Silence Therapeutics plc (SLN) on 06 Jan 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SLN
transaction
Derivative
Employee Share Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +900,000
- Change %
- Price
- $0.000000
- Shares after
- 900,000
- Date
- 02 Jan 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 900,000
- Exercise price
- $2.40
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
One fourth (1/4th) of the shares subject to the option shall vest on January 2, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.